drugset / Trial / NCT00932412

The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)

NCT00932412

Phase 2 Completed 735 enrolled Hospices Civils de Lyon
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a phase II randomized multicenter study. Patients will be enrolled at time of diagnosis and will receive one or two cycles of induction chemotherapy. Patients, without indication of intensification by allogeneic stem cell transplantation and/or without HLA (Human Leukocyte Antigen)-compatible donor, who attain a CR after one or two cycles of induction chemotherapy, will be eligible for the study Clofarabine / Intermediate-Dose Cytarabine (CLARA)versus High-Dose Cytarabine (HDAC)and will be randomized between 3 courses of CLARA chemotherapy and 3 courses of HDAC chemotherapy as consolidation. We will compare efficacy and toxicity among the two arms.

Timeline

Start
2009-03
Primary completion
2016-04
Completion
2016-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 30 mg/m2 Intravenous
Subject Cytarabine Small molecule 1 g Intravenous
Subject Cytarabine Small molecule 3 g Intravenous